IGF2 and hepatocellular carcinoma: Type 1 receptor (IGF1R) is reported to interact with insulin-like growth factor 1 and 2 (IGF1 and IGF2) for increasing fibrosis and impair liver functions from the start of preneoplastic alterations up to the developed hepatocellular carcinoma (HCC) stage (60).